Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice.
Hereditary haemophagocytic lymphohistiocytosis (HLH) is a fatal inflammatory disease and treatments currently may lead to serious side effects. There is a pressing need for effective, less toxic treatments for this disease. Previous reports have suggested that interferon gamma (IFNgamma) has a role in the pathogenesis of HLH. Here, we report that blocking IFNgamma had a therapeutic effect in two different murine models of human hereditary HLH (perforin-deficient and Rab27a-deficient mice, both infected with lymphocytic choriomeningitis virus). Therapeutic administration of an anti-IFNgamma antibody induced recovery from haemophagocytosis in both genetic models, as evidenced by increased survival in perforin-deficient mice and correction of blood cytopenia, moderation of body temperature changes, decreased cytokinaemia, restoration of splenic architecture and reduced haemophagocytosis in the liver of both murine models. Involvement of the central nervous system in Rab27a-deficient mice was prevented by anti-IFNgamma therapy. Hepatic T-cell infiltrates and virus persisted, with no detectable harm during the time course of these studies. These data strongly suggest that neutralization of IFNgamma could be used in humans to safely alleviate the clinical manifestations of haemophagocytosis.
Pachlopnik Schmid
Jana
J
Institut National de la Santé et de la Recherche Médicale, Unité U768, Laboratoire du Développement Normal et Pathologique du Système Immunitaire, Paris, France. jana.pachlopnik@inserm.fr
Ho
Chen-H
CH
Chrétien
Fabrice
F
Lefebvre
Juliette M
JM
Pivert
Gérard
G
Kosco-Vilbois
Marie
M
Ferlin
Walter
W
Geissmann
Frédéric
F
Fischer
Alain
A
de Saint Basile
Geneviève
G
D000818:Animals; D057134:Antibodies, Neutralizing / Q000494:pharmacology / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D001921:Brain / Q000187:drug effects / Q000473:pathology; D016207:Cytokines / Q000096:biosynthesis; D006801:Humans; D007371:Interferon-gamma / Q000276:immunology*; D008099:Liver / Q000187:drug effects / Q000276:immunology / Q000473:pathology / Q000821:virology; D008217:Lymphocytic choriomeningitis virus / Q000187:drug effects / Q000502:physiology*; D051359:Lymphohistiocytosis, Hemophagocytic / Q000097:blood / Q000188:drug therapy* / Q000821:virology*; D008262:Macrophage Activation / Q000187:drug effects; D051379:Mice; D009500:Neutralization Tests; D010587:Phagocytosis / Q000187:drug effects; D052899:Pore Forming Cytotoxic Proteins / Q000172:deficiency* / Q000378:metabolism; D013154:Spleen / Q000187:drug effects / Q000473:pathology; D016019:Survival Analysis; D020691:rab GTP-Binding Proteins / Q000172:deficiency* / Q000378:metabolism; D000075745:rab27 GTP-Binding Proteins
D057134:Antibodies, Neutralizing; D016207:Cytokines; D052899:Pore Forming Cytotoxic Proteins; C483886:perforin, mouse; D000075745:rab27 GTP-Binding Proteins; D007371:Interferon-gamma; C512962:Rab27a protein, mouse; D020691:rab GTP-Binding Proteins